Stock Research for FATE

FATE

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

FATE Stock Chart & Research Data

The FATE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the FATE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


FATE Due diligence Resources & Stock Charts

The FATE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View FATE Detailed Price Forecast - CNN Money CNN View FATE Detailed Summary - Google Finance
Yahoo View FATE Detailed Summary - Yahoo! Finance Zacks View FATE Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View FATE Trends & Analysis - Trade-Ideas Barrons View FATE Major Holders - Barrons
NASDAQ View FATE Call Transcripts - NASDAQ Seeking View FATE Breaking News & Analysis - Seeking Alpha
Spotlight View FATE Annual Report - CompanySpotlight.com OTC Report View FATE OTC Short Report - OTCShortReport.com
TradeKing View FATE Fundamentals - TradeKing Charts View FATE SEC Filings - Bar Chart
WSJ View Historical Prices for FATE - The WSJ Morningstar View Performance/Total Return for FATE - Morningstar
MarketWatch View the Analyst Estimates for FATE - MarketWatch CNBC View the Earnings History for FATE - CNBC
StockMarketWatch View the FATE Earnings - StockMarketWatch MacroAxis View FATE Buy or Sell Recommendations - MacroAxis
Bullish View the FATE Bullish Patterns - American Bulls Short Pains View FATE Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View FATE Stock Mentions - StockTwits PennyStocks View FATE Stock Mentions - PennyStockTweets
Twitter View FATE Stock Mentions - Twitter Invest Hub View FATE Investment Forum News - Investor Hub
Yahoo View FATE Stock Mentions - Yahoo! Message Board Seeking Alpha View FATE Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for FATE - SECform4.com Insider Cow View Insider Transactions for FATE - Insider Cow
CNBC View FATE Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for FATE - OTC Markets
Yahoo View Insider Transactions for FATE - Yahoo! Finance NASDAQ View Institutional Holdings for FATE - NASDAQ


Stock Charts

FinViz View FATE Stock Insight & Charts - FinViz.com StockCharts View FATE Investment Charts - StockCharts.com
BarChart View FATE Stock Overview & Charts - BarChart Trading View View FATE User Generated Charts - Trading View




Latest Financial News for FATE


Fate Therapeutics Announces Pricing of Public Offering of Common Stock
Posted on Thursday September 20, 2018

Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of 9,259,260 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts, for an aggregate offering of approximately $125.0 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,388,889 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $117.2 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters’ option.


Fate Therapeutics Announces Proposed Public Offering of Common Stock
Posted on Thursday September 20, 2018

Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of clinical product candidates and the conduct of preclinical research and development, and for general corporate purposes. All shares of common stock to be sold in the offering will be offered by Fate Therapeutics.


Why You Need To Look At This Factor Before Buying Fate Therapeutics Inc (NASDAQ:FATE)
Posted on Thursday September 20, 2018

If you own shares in Fate Therapeutics Inc (NASDAQ:FATE) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...


Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies
Posted on Monday September 17, 2018

Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a collaboration with ONO Pharmaceutical Co., Ltd. for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates. Using Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.